Innovotech Inc (IOT) - Net Assets
Based on the latest financial reports, Innovotech Inc (IOT) has net assets worth CA$3.65 Million CAD (≈ $2.64 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$4.43 Million ≈ $3.21 Million USD) and total liabilities (CA$784.68K ≈ $567.62K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Innovotech Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$3.65 Million |
| % of Total Assets | 82.3% |
| Annual Growth Rate | 6.81% |
| 5-Year Change | 209.98% |
| 10-Year Change | N/A |
| Growth Volatility | 184.04 |
Innovotech Inc - Net Assets Trend (2003–2025)
This chart illustrates how Innovotech Inc's net assets have evolved over time, based on quarterly financial data. Also explore IOT total asset value for the complete picture of this company's asset base.
Annual Net Assets for Innovotech Inc (2003–2025)
The table below shows the annual net assets of Innovotech Inc from 2003 to 2025. For live valuation and market cap data, see Innovotech Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CA$3.65 Million ≈ $2.64 Million |
+39.08% |
| 2024-12-31 | CA$2.62 Million ≈ $1.90 Million |
+162.68% |
| 2023-12-31 | CA$998.60K ≈ $722.37K |
-5.57% |
| 2022-12-31 | CA$1.06 Million ≈ $764.99K |
-10.15% |
| 2021-12-31 | CA$1.18 Million ≈ $851.37K |
+82.48% |
| 2020-12-31 | CA$644.98K ≈ $466.57K |
+557.56% |
| 2019-12-31 | CA$98.09K ≈ $70.95K |
+4.94% |
| 2018-12-31 | CA$93.47K ≈ $67.61K |
-48.50% |
| 2017-12-31 | CA$181.51K ≈ $131.30K |
+114.90% |
| 2016-12-31 | CA$-1.22 Million ≈ $-881.43K |
-21.49% |
| 2015-12-31 | CA$-1.00 Million ≈ $-725.51K |
-30.99% |
| 2014-12-31 | CA$-765.66K ≈ $-553.87K |
-34.48% |
| 2013-12-31 | CA$-569.33K ≈ $-411.85K |
-168.03% |
| 2003-12-31 | CA$836.94K ≈ $605.43K |
-0.53% |
| 2003-09-30 | CA$841.40K ≈ $608.65K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Innovotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 821798800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$11.83 Million | 328.82% |
| Total Equity | CA$3.60 Million | 100.00% |
Innovotech Inc Competitors by Market Cap
The table below lists competitors of Innovotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Soco Corporation Ltd
AU:SOC
|
$4.73 Million |
|
Noroo Holdings Co Ltd
KO:000325
|
$4.73 Million |
|
Nexgel Inc
NASDAQ:NXGL
|
$4.73 Million |
|
Trio Petroleum Corp.
NYSE MKT:TPET
|
$4.74 Million |
|
KST Beteiligungs AG
F:KSW
|
$4.72 Million |
|
Enlitic Inc
AU:ENL
|
$4.72 Million |
|
Nutritional Growth Solutions Ltd
AU:NGS
|
$4.71 Million |
|
Archidply Decor Limited
NSE:ADL
|
$4.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Innovotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,565,111 to 3,596,981, a change of 1,031,870 (40.2%).
- Net income of 94,375 contributed positively to equity growth.
- Other factors increased equity by 937,495.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$94.38K | +2.62% |
| Other Changes | CA$937.50K | +26.06% |
| Total Change | CA$- | 40.23% |
Book Value vs Market Value Analysis
This analysis compares Innovotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.82x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 22.31x to 1.82x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CA$0.01 | CA$0.12 | x |
| 2018-12-31 | CA$0.00 | CA$0.12 | x |
| 2019-12-31 | CA$0.00 | CA$0.12 | x |
| 2020-12-31 | CA$0.02 | CA$0.12 | x |
| 2021-12-31 | CA$0.03 | CA$0.12 | x |
| 2022-12-31 | CA$0.03 | CA$0.12 | x |
| 2023-12-31 | CA$0.02 | CA$0.12 | x |
| 2024-12-31 | CA$0.05 | CA$0.12 | x |
| 2025-12-31 | CA$0.07 | CA$0.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Innovotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.08%
- • Asset Turnover: 1.02x
- • Equity Multiplier: 1.23x
- Recent ROE (2.62%) is below the historical average (16.98%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | -1.62% | 0.00% | 0.00x | 1.05x | CA$-97.77K |
| 2003 | -1.74% | 0.00% | 0.00x | 1.00x | CA$-98.22K |
| 2013 | 0.00% | -93.07% | 2.10x | 0.00x | CA$-770.32K |
| 2014 | 0.00% | -23.23% | 2.21x | 0.00x | CA$-133.07K |
| 2015 | 0.00% | -35.41% | 3.32x | 0.00x | CA$-150.31K |
| 2016 | 0.00% | -21.43% | 3.09x | 0.00x | CA$-93.69K |
| 2017 | 415.07% | 76.07% | 1.88x | 2.90x | CA$735.23K |
| 2018 | -136.55% | -15.43% | 3.04x | 2.91x | CA$-136.98K |
| 2019 | -49.71% | -4.94% | 3.59x | 2.80x | CA$-58.57K |
| 2020 | 16.48% | 8.91% | 1.45x | 1.28x | CA$41.82K |
| 2021 | 31.19% | 24.78% | 1.03x | 1.22x | CA$249.44K |
| 2022 | -12.91% | -12.13% | 0.92x | 1.16x | CA$-242.26K |
| 2023 | -16.93% | -13.32% | 0.97x | 1.31x | CA$-250.64K |
| 2024 | 8.76% | 10.24% | 0.68x | 1.26x | CA$-31.78K |
| 2025 | 2.62% | 2.08% | 1.02x | 1.23x | CA$-265.32K |
Industry Comparison
This section compares Innovotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $12,408,933
- Average return on equity (ROE) among peers: -92.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Innovotech Inc (IOT) | CA$3.65 Million | -1.62% | 0.22x | $4.73 Million |
| Appili Therapeutics Inc (APLI) | $1.37 Million | -127.61% | 0.87x | $1.39 Million |
| Aptose Biosciences Inc (APS) | $45.89 Million | -12.51% | 0.05x | $4.30 Million |
| Arch Biopartners Inc (ARCH) | $-345.96K | 0.00% | 0.00x | $21.87 Million |
| Biomind Labs Inc (BMND) | $-247.66K | 0.00% | 0.00x | $7.01 Million |
| Cybin Inc (CYBN) | $86.12 Million | -37.41% | 0.07x | $301.37 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $-18.13 Million | 0.00% | 0.00x | $356.49 Million |
| Devonian Health Group Inc (GSD) | $4.13 Million | -44.17% | 1.44x | $22.43 Million |
| Helix BioPharma Corp. (HBP) | $2.98 Million | -302.25% | 0.65x | $88.40 Million |
| Hemostemix Inc (HEM) | $573.87K | -268.44% | 0.42x | $6.82 Million |
| Universal Ibogaine Inc (IBO) | $1.75 Million | -136.46% | 2.14x | $1.13 Million |
About Innovotech Inc
Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; and MBEC Assay kit, a screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms; pre-coated MBEC Assa… Read more